Aandeel Sangamo

Loading...

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

A-Z Keywords

Keyword Suggestions


Related pins: · Ice Wedging Diagram · Gurren Lagann Kamina Death ·